4-chloro-1-(2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine | 650628-61-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-chloro-1-(2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine
• 英文别名: 4-chloro-1-o-tolyl-1H-pyrazolo[3,4-d]pyrimidine；4-Chloro-1-(O-tolyl)-1H-pyrazolo[3,4-D]pyrimidine；4-chloro-1-(2-methylphenyl)pyrazolo[3,4-d]pyrimidine
• CAS: 650628-61-8
• 化学式: C₁₂H₉ClN₄
• mdl: MFCD08692090
• 分子量: 244.683
• InChiKey: FQPDDPVPETUUKP-UHFFFAOYSA-N

物化性质

• 沸点：
  341.8±42.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-1-(2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 (1-o-Tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-hydrazine
  参考文献：
  名称：

  Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors

  摘要：

  A series of [1-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]arylhydrazones were discovered as novel inhibitors glycogen synthase kinase-3 (GSK-3). Based on initial modeling a detailed SAR was constructed. Modification of the interior binding aryl ring (Art) determined this to be a tight binding region with little room for modification. As predicted from the model, a large variety of modifications could be incorporated into the hydrazone aryl ring. This work led to GSK-3 inhibitors in the low nano-molar range. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.036
• 作为产物：
  描述：

  (2-甲基苯基)肼 在 三乙胺 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 生成 4-chloro-1-(2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  新型GLUT抑制剂的鉴定

  摘要：

  使用HTS将1 H-吡唑并[3,4- d ]嘧啶类化合物鉴定为促进葡萄糖转运蛋白1（GLUT1）的非常有效的抑制剂。建立了分子框架每个环系统的广泛结构-活性关系研究（SAR），揭示了必要的结构动机（即，邻甲氧基取代的苯，哌嗪和嘧啶）。对GLUT2的选择性非常好，并且最初的体外和体内药代动力学（PK）研究令人鼓舞。

  DOI：

  10.1016/j.bmcl.2016.02.050

文献信息

• [EN] PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE SOUS FORME DE PYRAZOLOPYRIMIDINES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004009602A1

  公开（公告）日：2004-01-29

  The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.

  本发明一般涉及激酶的抑制剂，更具体地涉及新型吡唑吡嘧啶化合物。
• THERAPEUTIC AGENTS 414
  申请人：BENNETT Stuart Norman Lile

  公开号：US20100093757A1

  公开（公告）日：2010-04-15

  A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

  化合物Formula (I)在通过葡萄糖激酶（GLK或GK）介导的疾病或医疗状况的治疗或预防中很有用，导致胰岛素分泌的葡萄糖阈值降低。
• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2013182612A1

  公开（公告）日：2013-12-12

  The present invention relates to chemical compounds of general formula (I): in which RA, RB, RC, RD, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及通式(I)的化合物：其中RA、RB、RC、RD、m和n如描述和权利要求中所述，并且有效地且选择性地抑制葡萄糖转运蛋白1（GLUT1），以及制备该化合物的方法，包括含有该化合物的药物组合物和药物组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物的用途，以及在制备该化合物中有用的中间体化合物。
• [EN] PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS<br/>[FR] PYRAZOLOPYRIMIDINES UTILISES COMME AGENTS ANTI-HEPATITE C
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2005047288A1

  公开（公告）日：2005-05-26

  Pyrazolopyrimidine derivatives of formula (I), or a pharmaceutically acceptable salt thereof, are found to be active against hepatitis C infection, wherein: R1 is C6-C10 aryl, 5- to 10- membered heteroary1, -(C1-C4 alkyl)-(C6-C10 aryl) or -(C1-C4 alkyl)-(5- to 10- membered heteroaryl); R2 is a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C6­C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10­membered heterocyclic ring; and X is -NR'-, -NR'-CO-NR''-, -NR'-L, or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C1-C6 alkyl group and L represents a C1-C6 alkylene group, the aryl, heteroaryl, heterocyclyl. and carbocyclyl moieties in the R1 and R2 substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl C1-C4alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'­CO2-R'', -CO2R'', -COR'''-NR'-CO-R''',-CONR'R'',SO2NR'R'',SO2R'''and -O-(CH2)n-R''' substituents, wherein n is from 0 to 4, each R’is the same or different and is hydrogen or C1-C6 alkyl, each R'' is the same or different and is hydrogen, C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, and each R'''' is the same or different and is C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C1-C4 alkyl, C1-C4 hydroxyalkyl and C1-C4 haloalkyl groups.

  式(I)的吡唑啉衍生物，或其药用可接受的盐，被发现对丙型肝炎感染具有活性，其中：R1为C6-C10芳基，5-到10-成员杂芳基，-(C1-C4烷基)-(C6-C10芳基)或-(C1-C4烷基)-(5-到10-成员杂芳基)；R2为C6-C10芳基，C3-C6碳环烷基，5-到10-成员杂芳基或5-到10-成员杂环烷基基团，该基团可选择地与C6-C10芳基，C3-C6碳环烷基，5-到10-成员杂芳基或5-到10-成员杂环烷基环融合；X为-NR'-，-NR'-CO-NR''-，-NR'-L，或-NR'-CO-L-，其中R'和R''相同或不同，分别代表氢或C1-C6烷基，L代表C1-C6烷基基团，R1和R2取代基中的芳基，杂芳基，杂环烷基和碳环烷基基团未取代或通过1、2或3个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基、氰基、硝基、C6-C10芳基、C3-C6碳环烷基、5-到10-成员杂环烷基、5-到10-成员杂芳基、-NR'-CO2-R''、-CO2R''、-COR'''-NR'-CO-R'''、-CONR'R''、SO2NR'R''、SO2R'''和-O-(CH2)n-R'''取代。
• The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold
  作者：Peter Bonn、D. Mikael Brink、Jonas Fägerhag、Ulrik Jurva、Graeme R. Robb、Volker Schnecke、Anette Svensson Henriksson、Michael J. Waring、Christer Westerlund

  DOI：10.1016/j.bmcl.2012.10.090

  日期：2012.12

  Glucokinase is a key enzyme in glucose homeostasis since it phosphorylates glucose to give glucose-6-phosphate, which is the first step in glycolysis. GK activators have been proven to lower blood-glucose, and therefore have potential as treatments for type 2 diabetes. Here the discovery of pyrazolopyrimidine GKAs is reported. An original singleton hit from a high-throughput screen with micromolar levels of potency was optimised to give compounds with nanomolar activities. Key steps in this success were the introduction of an extra side-chain, which increased potency, and changing the linking functionality from a thioether to an ether, which led to improved potency and lipophilic ligand efficiency. This also led to more stable compounds with improved profiles in biological assays. (C) 2012 Elsevier Ltd. All rights reserved.